Physician profile
Brooke Matthews
NPI 1093271918
$3,774.72
in general payments reported to CMS, 2019-2025
22 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $816 · 2023: $824 · 2024: $740 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.22 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,173.57 | 2021-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Gilead Sciences, INC. | $385.10 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $357.41 | 2021-2025 | Dificid, Delstrigo, Pifeltro |
| La Jolla Pharmaceutical Company | $330.12 | 2021-2024 | Xerava |
| Paratek Pharmaceuticals, INC. | $276.47 | 2021-2024 | Nuzyra |
| Astellas Pharma US INC | $205.28 | 2021-2023 | Cresemba |
| Janssen Biotech, INC. | $199.29 | 2021-2022 | |
| Viiv Healthcare Company | $144.27 | 2021-2025 | Dovato |
| Abbvie INC. | $139.99 | 2021-2024 | |
| Shionogi INC | $138.72 | 2022-2024 | Fetroja |
| Grifols USA, LLC | $79.46 | 2024-2025 | Xembify |
| Stryker Corporation | $59.55 | 2025 | Clottriever Bold Catheter |
| Boston Scientific Corporation | $51.57 | 2025 | Rezum Generator |
| Insmed, INC. | $50.83 | 2023-2025 | Arikayce |
| Janssen Products, LP | $31.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.96 | 2022 | |
| Aimmune Therapeutics, INC. | $26.91 | 2023 | |
| Octapharma USA, INC. | $22.25 | 2023 | Panzyga |
| X4 Pharmaceuticals, INC. | $21.90 | 2025 | Xolremdi |
| Mayne Pharma Commercial LLC | $17.22 | 2021 | |
| Theratechnologies INC. | $16.85 | 2023 | Trogarzo, Egrifta |
| Cumberland Pharmaceuticals, INC. | $16.51 | 2023 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.